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Abstract
Background: Hepatocellular carcinoma (HCC) presents one of the major health threats in China today.
A better understanding of the molecular genetics underlying malignant transformation of hepatocytes is
critical to success in the battle against this disease. The methylation state of C5 of the cytosine in the CpG
di-nucleotide that is enriched within or near the promoter region of over 50 % of the polymerase II genes
has a drastic effect on transcription of these genes. Changes in the methylation profile of the promoters
represent an alternative to genetic lesions as causative factors for the tumor-specific aberrant expression
of the genes.
Methods: We have used the methylation specific PCR method in conjunction with DNA sequencing to
assess the methylation state of the promoter CpG islands of twenty genes. Aberrant expression of these
genes have been attributed to the abnormal methylation profile of the corresponding promoter CpG
islands in human tumors.
Results: While the following sixteen genes remained the unmethylated in all tumor and normal tissues:
CDH1, APAF1, hMLH1, BRCA1, hTERC, VHL, RARβ, TIMP3, DAPK1, SURVIVIN, p14ARF, RB1, p15INK4b,
APC, RASSF1c and PTEN, varying degrees of tumor specific hypermethylation were associated with the
p16INK4a , RASSF1a, CASP8 and CDH13 genes. For instance, the p16INK4a was highly methylated in HCC
(17/29, 58.6%) and less significantly methylated in non-cancerous tissue (4/29. 13.79%). The RASSF1a was
fully methylated in all tumor tissues (29/29, 100%), and less frequently methylated in corresponding non-
cancerous tissue (24/29, 82.75%).
Conclusions: Furthermore, co-existence of methylated with unmethylated DNA in some cases suggested
that both genetic and epigenetic (CpG methylation) mechanisms may act in concert to inactivate the
p16INK4a and RASSF1a in HCC. Finally, we found a significant association of cirrhosis with hypermethylation
of the p16INK4a and hypomethylation of the CDH13 genes. For the first time, the survey was carried out
on such an extent that it would not only provide new insights into the molecular mechanisms underscoring
the aberrant expression of the genes in this study in HCC, but also offer essential information required for
a good methylation-based diagnosis of HCC.
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Background
Hepatocellular carcinoma (HCC) presents a major health
threat in South-East Asia, especially in China. It rates third
among all malignancies both in incidence and modality
in China and accounts for approximately 42.5% of the to-
tal incidence worldwide [1,2]. Its rapidly advancing na-
ture makes early detection a crucial prognostic factor.
Despite many years of sustained efforts, the long-term
outcome employing current therapies remains dismal as
both recurrences of the lesions within the liver and distant
metastases are not rare occurrences. Both chronic hepatitis
B viral infection and exposure to α-flatoxin B1 are the two
most important risk factors associated with this disease
[3].
Cancer is a disease in which cells suffer from multiple ge-
netic changes resulting in the aberrant expression of many
genes which in turn form tumor specific phenotypes [4–
7]. Mechanistically, the methylation mediated gene si-
lencing mechanism can contribute to the tumor specific
profile of gene expression, as a common alternative to ge-
netic changes. In higher vertebrates, the major, if not the
only, covalent modification of DNA is the C5 methyl cy-
tosine within the CpG di-nucleotides which are signifi-
cantly under-represented in genomes but frequently
concentrated within short pieces of DNA segments, desig-
nated as "CpG islands" [6,8]. The enzymes responsible for
this chemical reaction are the DNA methyl transferase I
and IIIA as well as IIIB [6,8]. The DNA methyl transferase
I is mainly involved in maintenance of the methylation
status of genomes through DNA replication, whereas
DNA methyl transferase IIIA and IIIB act principally for
the de novo DNA methylation in the early stages of devel-
opment [6,7]. Over 50% of the protein coding genes have
at least one CpG island within or near their promoters, ex-
pressions of which are sensitive to the methylation status
of such CpG islands [7]. The methylation profiles of the
promoter CpG islands have been useful indicators for the
transcriptional state of the genes in a large number of, if
not all, cases. The hypermethylated promoters lack the
transcriptional activity that may account for gene inactiva-
tion both in normal physiological and disease states, no-
ticeably the inactivation of the tumor suppressor genes in
cancers [7,9–11]. Elevated levels of expression of the DNA
methyl transferase I have been frequently observed in can-
cers and may have a causal role in hypermethylation-me-
diated gene silencing of the tumor suppressor genes. On
the other hand, the genes that lack expression and have
hypermethylated promoter CpG islands in normal cells
may be reactivated by promoter demethylation in tumor
cells [7]. However, there was evidence for the global level
of hypomethylation in tumors, the consequence of which
is genome instability in tumor cells [12,13]. Therefore,
there must be a gene-specific mechanism for determining
the methylation profile of the promoter CpG islands both
in normal and tumor cells, which correlates well with the
expression profile of the genes.
Many recent studies demonstrated that the DNA methyla-
tion based mechanism can contribute to inactivation of
tumor suppressor genes, key event in tumorgenesis of a
wide spectrum of human tumors [7,9–11], including
HCC [14,15]. However, the overwhelming majority of, if
not all, such studies have dealt with only one or just a few
genes. This was particularly true in regard to human HCC
for which only p16INK4a, p15INK4b and p14ARF genes have
been investigated [15,16]. Previously, whether there were
any associations in the methylation profiles of different
genes may have been an impossible issue to address. In
this report, we surveyed the methylation profiles for as
many as twenty genes in both HCC tissues and adjacent
non-cancerous tissues of twenty-nine patients (Table 1).
Furthermore, we included the DNA from four healthy do-
nors as the most stringent control for the pattern of pro-
moter CpG island methylation in normal liver tissues.
Sixteen genes including CDH1, APAF1, hMLH1, BRCA1,
hTERC, VHL, RAB β, TIMP3, DAPK1, SURVIVIN, p14ARF,
RB1, p15INK4b, APC and PTEN had the same DNA meth-
ylation pattern in all samples, including the cancerous
and corresponding non-cancerous tissue from patients as
well as the normal liver tissue from healthy donors. The
methylation mediated mechanisms, therefore, may have
no significant roles to play in expression of these sixteen
genes in HCC. On the contrary, the methylation profiles
of the p16INK4a, RASSF1a, CDH13 and CASP8 genes var-
ied with the patient samples to varying degrees. Further-
more, among all possible associations with the clinical-
pathological parameters being considered, we found a
tight link between hypermethylated p16INK4a  and hy-
pomethylated CDH13 on one hand and cirrhosis on the
other. Our results should not only enhance our under-
standing of the molecular epigenetic mechanisms under-
scoring hepatocarcinogenesis, but also facilitate the
development of robust early diagnostic tools based on the
DNA methylation profile for human HCC in China.
Methods
Cell lines and tissue samples
With the informed consent of all patients and donors and
approval of the ethics committee, the samples of tumor
and adjacent non-cancerous tissues were collected from
HCC patients (n = 29) (Table 1) during surgery at The Qi-
dong County Hospital, The Oriental Institute for Liver
Diseases and Guangxi Provincial Hospital, respectively. In
addition, normal liver tissues (n = 4) were obtained from
liver donors at the Liver Transplantation Unit in The First
Affiliated Hospital, College of Medicine, Zhejiang Univer-
sity The pathological classification of HCC tissues was car-
ried out and the stage of each HCC was determinedBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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according to criteria outlined by the Liver Cancer Study
Group of Japan[40].
Total genomic DNA was extracted from frozen tissue spec-
imens (50 – 100 mg) according to standard protocol [18]
with some modifications, which are briefly described be-
low. Frozen pulverized powders of the specimens were re-
suspended with 2 ml warmed lysis buffer: 50 mM Tris-
HCl pH 8.0, 50 mM EDTA, 1% SDS, 10 mM NaCl plus
100 µg/ml boiling-treated RNase A (Sigma). Following
one hour of incubation at 37ºC, Proteinase K (Roche,
USA) was added to the cellular lysates for a final concen-
tration of 100 µg/ml and the digestion was carried out at
55ºC for 2 hours. Organic extractions with a half volume
of Phenol/Chloroform/Isoamyl alcohol (1:1:0.04) were
repeatedly carried out until no visible interphase re-
mained after centrifugation. DNA was precipitated from
the aqueous phase in the presence of 0.3 M NaOAc pH 7.0
and two and a half volumes of ethanol. The DNA pellet
was washed once with 70% ethanol and dissolved at
65ºC for 30 minutes with 0.2 – 0.4 ml TE (10 mM Tris
HCl pH 7.4 and 1 mM EDTA), followed by storage at 4ºC
until further use. The DNA concentrations were calculated
according to their OD260nm readings.
The genomic DNA was also prepared from tumor cell
lines: SMMC 7721 (an established human cell line from a
human hepatocellular carcinoma, Catalogue No, TCHu13
in Cell Bank in China), HuH-7 (a human liver cancer cell
line, JCRC No. JCRB0403), Hep 3B (a human hepatoma
cell line, ATCC No., HB-8064), Hep G2 (a human hepato-
ma cell line, ATCC No., HB-8065) and U20s (an osteosa-
rcoma cell line, ATCC No.HTP96,) and stored in TE buffer
at 4ºC.
Bisulphate treatment of DNA and MSP
The methylation status of the promoter CpG islands of
twenty genes (Additional file 1) in all sample DNA were
analyzed by MSP on the sodium-bisulfite converted DNA
[18]. All chemicals at analytic grade were obtained from
Shanghai Chemical Cooperation, China and the experi-
mental procedure was customized by using genomic DNA
of SMMC7721 and U20S cells. In detail, 10 µg DNA in 50
µl TE was incubated with 5.5 µl of 3 M NaOH. at 37°C for
Table 1: Clinical pathological parameters of HCC patients
No. Patient Age Sex Cirrhosis HBV infection AFP 
(serum level)
Grading
1 D1 56 M - + 10.9 µg/l I
2 D14 33 F - + 1000 µg/l II
3 D15 65 F + + 183. µg/l II
4 D16 51 M + + 2590 µg/l I
5 D17 37 M + + 1000 µg/l III
6 D18 61 M - + 2.5 µg/l I
7 D24 36 M + + 10.6 µg/l III
8 D59 70 M + + 27.6/µg/l I
9 Z82 55 F + + 385 µg/l I
10 Z85 57 M + + 415 µg/l
11 Z89 42 M + + 10 µg/l III
12 Z90 67 M + + 141 µg/l II
13 Z92 44 M + + 1208 µg/l II
14 G33 36 F + + 400 µg/l II
15 G35 38 M + + 12 µg/l II
16 G36 72 M + + 1416 µg/l I
17 G41 56 M + + 10 µg/l I
18 G44 62 M + + 10 µg/l II
19 G47 44 M - + 346 µg/l I
20 G62 46 M - + 16 µg/l II
21 G63 42 M - + 3.7 µg/l III
22 G64 42 M - + 4000 µg/l II
23 G65 35 F - + 400 µg/l III
24 Q45 61 M - + 400 µg/l II
25 Q46 50 F - + 400 µg/l II
26 Q47 52 M - + 30 µg/l II
27 Q48 48 M - + 38 µg/l I
28 Q49 42 M - + 400 µg/l II
29 X63 37 M + + IIBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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10 minutes, followed by a 16 hour treatment at 50°C after
adding 30 µl of freshly prepared 10 mM hydroquinone
and 520 µl of freshly prepared 3.6 M sodium-bisulfite at
pH 5.0. The DNA was desalted using a home dialysis sys-
tem with 1% agarose (detailed protocol will be provided
upon request). The DNA in the desalted sample (approx-
imately 100 µl in volume) was denatured at 37°C for 15
minutes with 5.5 µl of 3 M NaOH followed by ethanol
precipitation with 33 µl 10 M NHaOAC and 300 µl etha-
nol. After washing with 70% ethanol, the gently dried
DNA pellet was dissolved with 30 µl TE at 65°C for 10
min. The DNA sample was finally stored at -20°C until
further use. The sample of 50 ng of DNA was reserved for
PCR reaction.
PCR reaction was carried out in a volume of 15 µl with 50
ng or less template DNA with FastStart Taq polymerase
(Roche, Germany) as follows. After an initial heat dena-
turing step 4 minutes treatment at 94°C), 30 cycles of
92°C for 15 sec, varying temperatures with primer pairs
(Additional file 1) for 15 sec and 72°C for 20 sec, was car-
ried out. The PCR products were separated by 1.2 % ethid-
ium bromide containing agarose gel electrophoresis with
1 X TAE and visualized under UV illumination. To verify
the PCR results, representative bands from each target
were gel-purified and cloned into T-vector (Promega,
USA) followed by automatic DNA sequencing provided
by Genecore (Shanghai, China). Only verified results are
presented in this report.
Southern analyses with the methylation sensitive enzyme 
of the promoter CpG islands of the p14ARF  and p15 INK4b  
genes in hepatoma cell lines
30 microgram of the genomic DNA from the HepG2, Hep
3B, and HuH-7 cell lines were digested to completion
with BstX I (for p14ARF) and Hind III (for p15INK4b), re-
spectively. Following ethanol precipitation, 10 microgram
of the digests was restricted to completion with Hap II and
Msp I enzymes, respectively. The digested DNA was etha-
nol precipitated and subjected to Southern analysis ac-
cording the previously published protocol [43].
The DNA fragments for the hybridization probes were
made by PCR reaction on the HepG2 DNA. The primers
are ordered according to the genomic sequence of the rel-
evant gene locus (Accession No. AL449423 in GenBanK),
namely, 1, for the p14ARF gene: the sense: 5' GAG TTT
GAG CAT GTG CAA TGT TAG G 3'; the anti-sense: 5' GGG
ATT ATT ACT CCT GTT TTA CAG GTG 3'; 475bp in size
(89561–90035) and 2, the p15INK4b: the sense : 5' CCT
GTT TTA CGC GTG GAA T 3' and the anti-sense: 5' TAA
TGA AGC TGA GCC CAG GT 3'; 437bp in size (99391–
99827). The resulted PCR fragments were labeled with the
random labeling kit (Roch, Germany) in presence of 32p-
dCTP (Amersham, UK). The labeled probes were chroma-
tographically purified from free nucleotides, heat-dena-
tured, hybridized to the blots. The post-hybridization
washing of the membranes was carried out with 1 X SSC,
0.1 %SDS at 42 ºC for 30 minutes for three times. The hy-
bridized bands were revealed in the phosphoimager Ty-
phoon 9410(Molecular dynamics, USA).
Results and Discussion
Clinical-pathological considerations
The geographical occurrence of HCC varies dramatically
within China. In areas such as Qidong county near Shang-
hai and Guangxi province, well known high incidence ar-
eas, the annual incidence of HCC is as high as 70 – 96/
10,0000 and approximately eight to nine fold higher than
that of low incidence areas within China [1,3]. Two com-
mon risk factors identified in these regions are persistent
hepatitis B viral infections and α-flatoxin B contamina-
tion of food stocks[3]. To address the geographic aspect of
this disease, we deliberately recruited nineteen patients in
Shanghai area (including eight patients from Qidong
county) and ten patients from GuangXi province in the
southern part of China. As shown in Table 1, all patients
were HBV infected verified by both serological analysis
and the PCR test for existence of the HBV X gene in tumor
tissue (not shown). As indicated in Table 2, no significant
differences for any of the clinical pathological indicators
between these two geographically classified patient
groups were detected. For instance, male patients account-
ed for 78.9% and 80%, cirrhosis occurred in 58 % and 50
Table 2: Clinical pathological considerations of HCC sub-groupings according to geographic origin
Sex Grading Cirrhosis
F M I II III + -
SHANGHAI 
(n = 19)
4 15 5 (28%) 8 (44%) 5 (28%) 11 (58%) 8 (42%)
GUANGXI 
(n = 10)
2 8 3 (30%) 4 (40%) 3 (30%) 5 (50%) 5 (50%)
*The total cirrhosis positive rate is 16/29 (55%)BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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% of patients and diagnoses of grade I were 28% and 30%,
grade II were 44% and 40 % and grade III were 28% and
30 % of the Shanghai and Guang Xi patient groups, re-
spectively. Therefore, the remaining analyses were carried
out without any consideration of geographic impact.
Special efforts were made to include the corresponding
non-cancerous tissues, samples of which were overlooked
in all previous studies of HCC [14,15]. Furthermore, path-
ological examination of the tissues had been carried out to
eliminate samples in which contamination of undesirable
tissues exceeded 20%. To emphasize the HCC specificity
of this study, four samples of normal liver tissue were col-
lected from the Liver Transplantation Unit of the Zhejiang
First Hospital as the normal liver control.
The genes with no HCC associated alteration in the meth-
ylation profiling
Among several dozens of targets in the category of the
CpG island containing genes http://www.missouri.edu/
~hypermet/list_of_promoters.htm, we assessed the pro-
moter CpG islands of twenty genes well recognized for
their roles in carcinogenesis and expressions of which are
affected by the methylation status of each promoter CpG
island. There are TSP genes in the RB/p16 pathway: RB1,
p16INK4a  and p15INK4b; in the p53 pathway: p14ARF;
genes involved in intercellular interaction: CDH1,
CDH13, TIMP3 and RAR-β; genes involved in DNA repair:
hMLH1, and BRCA1; genes involved in apoptosis, APAF1,
DAPK1, CASP8 and SURVIVIN and several other TSP
genes: RASSF1a and RASSF1c, VHL, APC and PTEN. Final-
ly, the hTERC gene was included in this study, the encod-
ed RNA of which is the key component of the telomerases
acting against replication dependent shortening of telom-
Table 3: Cirrhosis and methylation profiles of the genes in HCC tissues
Patient Cirrhosis Grading CDH13 p16INK4a RASSF1A CASP8
D24 + III U M M M
D17 + III U M M M
X63 +I IUU M
Z89 + III U M M M
Z92 + I IMMMM
D16 +IU U M M
Z82 +IU M M
Z85 +U M M
D15 +I IU M M M
Z90 +I IU M M M
D59 +IU M M M
G33 +I IUU M M
G35 +I IU M M M
G41 +IU M M M
G44 +I IUU M
G36 +IU M M M
Total (%) C/T(16) 100% M/T(16) 6.25% M/T(16) 75% M/T(16) 100% M/T(12) 100%
D18 - I MUMM
Q45 -I IU U M
G65 - III U U M
D1 -IU M M M
Q47 - I IMMMM
G63 - III U M M M
G64 -I IU U M
G47 -IU U M M
G62 - III M M M M
D14 -I IU U M M
Q49 -I IU U M
Q48 - I MUMM
Q46 - I IMUM
Total (%) C/T(13) 0% M/T(13) 38.46% M/T(13) 30.76% M/T(13) 100% M/T(8) 100%BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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eres and the over-expression of which correlates with
demethylation of the promoter CpG islands in human
breast carcinoma [17].
Differing from the methylation-sensitive restriction en-
zymes that are limited to a subset of CpG-cytosine, meth-
ylation specific PCR (MSP) in conjunction with
sequencing allows the analysis of the methylation status
of all the CpGs within the targeted CpG islands. MSP dis-
tinguishes unmethylated from methylated alleles based
on the sequence changes created by bisulfite treatment of
DNA, which are recognized by PCR with one of two pairs
of primers designated for either methylated or unmethyl-
ated DNA. [18] To ensure the relativity of our study with
others [9,10,18–26], we chose the same CpG regions se-
lected by other researchers as study targets (see Additional
file 1). For genes not previously investigated, the primers
were designed with special care in regard to both location
and size of CpG islands. As shown in Additional file 1, the
genes in this category are APAF1, CDH13, PTEN, RASSF1c
and SURVIVIN. Finally, the representative methylated and
unmethylated PCR products were cloned into T-vectors
and sequenced for data verification. Since all DNA sam-
ples were batch-treated chemically and analyzed with
each of 40 pairs of primers using the MSP approach re-
spectively, observations from each PCR reaction were mu-
tually controlled by each of the remaining 39 PCR
reactions with different pairs of primers. Therefore, the in-
fluences over experimental data have been well eliminat-
ed by factors including the under- or over-treatment of
DNA by sodium-bisulfite; contamination of the unde-
sired types of tissues to the samples should have been
minimized.
As indicated in both Fig. 1, Fig. 2 and Additional file 2, six-
teen targets including p14ARF (Fig. 1, panel 1), p15INK4b
(Fig. 1, panel 2), SURVIVIN (Fig. 1, panel 7), TIMP3 (Fig.
1, panel 8), VHL (Fig. 1, panel 9), APC (Fig. 2, panel 1),
RASSF1c (Fig. 1, panel 10)APAF1 (Fig. 2, panel 2), BRCA1
(Fig. 2, panel 3), DAPK1 (Fig. 2, panel 4), CDH1 (Fig. 2,
panel 5), hMLH1 (Fig. 2, panel 6), hTERC (Fig. 2, panel
7), PTEN (Fig. 2, panel 8), RAR-β (Fig. 2, panel 9), and
RB1 (Fig. 2, panel 10), had a consistent pattern among all
tissues tested, including cancerous and counterpart non-
cancerous tissues from twenty-nine patients with hepato-
carcinoma along with donated normal liver tissue from
four healthy controls. All the targets in this category were
unmethylated, which came as a surprise in view of many
recent published data showing that a significant propor-
tion of tumor cases, from a large spectrum of tissue ori-
gins, had one or several genes in the list inactivated via the
methylation mediated genes silencing mechanism. One
may consider all the following plausible explanations. 1.
These genes may not have had any significant role to play
in carcinogenesis of the human HCC and did not suffer
any functional loss in cancerous tissues due to any genetic
or epigenetic mechanisms. 2. The defects of the pathways
where these genes preside had been caused by genetic or
epigenetic aberrations targeted to the genes acting either
upstream or downstream of the genes listed. 3. The func-
tional loss of these genes may indeed happen in HCC, but
the mechanism involved is not related to DNA methyla-
tion. 4. Again, the functional loss of these genes which
happens in HCC may be attributed to methylation-medi-
ated gene silencing mechanisms. However, the changes in
methylation profile may have occurred at the CpG island
rather than the one being analyzed in this report. Obvi-
ously, which of the aforementioned mechanisms contrib-
uted to the observed methylation profile for each of these
sixteen genes (Fig. 1 and 2 and Additional file 2) remains
to be determined. Tumor specific inactivation of these six-
teen genes caused by hypermethylation of the promoter
CpG island has been widely claimed in a variety of solid
tumors. For instance, the TIMP3 gene encodes an inhibi-
tor of metalloproteinase 3 and is thought to suppress pri-
mary tumor growth [23,29]. Its promoter CpG island was
methylated in 19 – 26 % of the non-small cell lung can-
cers[23]. The lack of hypermethylation of all these pro-
moter CpG islands in our study of human HCC may have
differential diagnostic value between human HCC and
other human tumors when a serum DNA-methylation
profiling-type diagnostic assay has been developed.
Wong et al. have reported that the promoter CpG islands
of the p14ARF and p15INK4b were methylated in a signifi-
cant percentage of HCC cases in Hong Kong [14,15],
while neither were methylated in this study (Fig. 1 and 2
and Additional file 2). As the target CpG islands in these
two studies are identical and our MSP results were verified
by DNA sequencing, the discrepancy between our work
and that of Wong may reflect the difference in the geo-
graphical related risk factors between Hong Kong and
Shanghai/Guangxi. However, to eliminate a remote possi-
bility that failure to detect the methylated CpG islands of
these two genes in our hand might result from the inade-
quacy of the MSP approaches used in this report, we re-
peated this analysis with an alternative approach in which
no PCR process is involved, i.e., the digested DNA with
methylation sensitive enzyme (Hpa II) or insensitive en-
zyme (Msp I) was analyzed by Southern hybridization
with the probes from the promoter CpG islands of the
p14ARF and p15INK4b, respectively (Fig. 3). We deliberate-
ly used the same enzymes and probing fragments that had
been used previously [41,42]. Limited by the shortage of
the patient's DNA samples, the genomic DNA from three
established hepatoma cell lines, i.e., HepG2, Hep 3B and
HuH-7 were used instead in these two experiments, the
CpG islands of which were unmethyated by MSP analysis
(Fig. 3, panel 2). The DNA was batched digested with
Hind III (for p15INK4b) [41] and BstX I (for p14ARF) [42],BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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Figure 1
The methylation profiles of ten genes in human HCC patients (part 1). Both electrophoretic patterns of the repre-
sentative PCR products of ten targets (indicated respectively at the top of figures) and the corresponding sequencing result of 
the one representative PCR product were presented. To indicate the methylation status, the sequenced data are aligned with 
the wild-type sequence. Representative samples are presented. * size marker. U, the unmethylated; and M, the methylated.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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Figure 2
The methylation profiles of ten genes in human HCC patients (part 2). Both electrophoretic patterns of the repre-
sentative PCR products of ten targets (indicated respectively at the top of figures) and the corresponding sequencing result of 
the one representative PCR product were presented. To indicate the methylation status, the sequenced data are aligned with 
the wild-type sequence. Representative samples are presented. * size marker. U, the unmethylated; and M, the methylated.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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Figure 3
The methylation profiles of the p14ARF and p15INK4b genes in the hepatoma cell lines analyzed by both MSP 
and Southern analyses. Panel 1, The schematic illustration of the gene structure and the CpG islands of interests along with 
restriction digestion sites and the probes. The scale is arbitrary. Panel 2, The methylation profiling of the p14ARF and p15INK4b 
promoter CpG island by MSP. Panel 3, The schematic illustration of the CpG islands of p14ARF with restriction digestion sites 
and the probes. Panel 4, The electrophoretic pattern of the digests before blotting of the genomic DNA. The cell origins of the 
genomic DNA are indicated at the top. The size markers are provided by Hind III digests of the lambda phage DNA and indi-
cated in kb at the left side of the autorad. Abbreviations: B, BstX I; H: Hpa II, M: Msp I. Panel 5, The autorad of the Southern 
analysis hybridized by the probe indicated in panel 3. The size of the hybridized band is indicated at the left side of the antorad. 
Panel 6, The schematic illustration of the CpG islands of p14ARF with restriction digestion sites and the probes. Panel 7, The 
electrophoretic pattern of the digests before blotting of the genomic DNA. The cell origins of the genomic DNA are indicated 
at the top. The size markers are provided by Hind III digests of the lambda phage DNA and indicated in kb at the left side of the 
autorad. Abbreviations: Hi: Hind III; H: Hpa II, M: Msp I. Panel 8, The autorad of the Southern analysis hybridized by the probe 
indicated in panel 6.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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and the one third of the former digests were restricted by
Hpa II (methylation sensitive) and Msp I (methylation in-
sensitive), respectively. As shown by panels 4 and 7, Fig.
3, the DNA for the Southern analyses were likely digested
to completion and the DNA loading were fully compati-
ble among different lanes. Both Hind III and BstX I diges-
tion produced the fragments of the expected sizes: 5.7 kb
in Fig. 3, panel 5 for p14ARF and 2.5 kb in Fig. 3, panel 8
for p15INK4b. The additional digestion with Hap II or Msp
I led to the disappearance of the original bands of the
former single digests, suggesting the CpG islands being
studied were unmethylated. Since the downstream probe
of the CpG island of p14ARF (Fig. 3, panel 3) was used, the
smaller fragments of approximately 2.4 kb in size were
produced. It was noticed that the Hap II digestion pro-
duced a band bigger than that by Msp I digestion in both
Hep3B and HuH-7 cells (Fig. 3, panel 5). This might result
from the incomplete digestion of Hpa II. In the compati-
ble study of the p15INK4b gene, the probe was used within
the CpG island (Fig. 3, panel 6), the efficient digestion by
Hpa II or Msp I had resulted in loss of the parental band
of the Hind III digests (Fig. 3, panel 8), again suggesting
that the promoter CpG island of the p15INK4b gene is un-
methylated. Therefore, our conclusion based on the MSP
analysis on the HCC patient samples in this report is
sound.
The genes with the HCC specifically altered methylation 
profiles
Contrary to the sixteen genes listed above, p16INK4a,
RASSF1a, CDH13 and CASP8 (panels 3–6, respectively, in
Fig. 1) possessed the tumor specific altered pattern of
methylation of the promoter CpG islands, suggesting that
the DNA methylation mediated mechanisms may have a
causal role in inactivation (if there is any) of the those
genes in HCC in these two regions in China.
The hypermethylation of the promoter CpG island of the p16INK4a 
may occur at a very late stage within the multiple stage processes of 
hepatocellular carcinogenesis
The p16INK4a is one of the most commonly inactivated tu-
mor suppressor gene in human cancers[30] and encodes a
cyclin-dependent kinase inhibitor. This tumor suppressor
protein negatively regulates cell progression from the G1
to the S phase by binding and inhibiting the cyclin-de-
pendent kinases 4 and 6, which in turn repress RB func-
tion via phosphorylation of the RB tumor suppressor
protein.[28]. Hypophosphorylated RB proteins bind to
the DNA bound form of the E2F/Dp-1 complexes, repress-
ing expression of the genes, functions of which are re-
quired for cell entry from G1 to S phase.
Hyperphosphorylation of RB protein by cyclin-dependent
kinases would dissociate RB protein from the E2F/DP1
complexes to allow the otherwise silenced transcription to
occur. The paramount importance of this RB/p16INK4a
mediated control to maintain the normality of cell is viv-
idly demonstrated by the prevalent loss of this control in
human tumors[10,23]. Both genetic and epigenetic mech-
anisms resulting in inactivation of the RB1 or p16INK4a
genes have been highlighted in many human tumors
[10,11,15,16,19,23,31]. Another cyclin-dependent kinase
inhibitor within the proximity of and sharing 91% se-
quence identity with the p16INK4a gene is p15INK4b [32].
This p15INK4b gene may have a similar tumor suppressor
function as the p16INK4a by modulating pRB phospohr-
ylation[33], since its promoter CpG island was aberrantly
methylated in several human tumors [14,18,19,34], in-
cluding the human HCC [14]. In this report, we assessed
the methylation profile of the promoter CpG island of the
RB1 (encoding TSP and RB), p16INK4a and p15INK4b genes
in the HCC samples along with the normal liver controls.
As indicated in Fig. 1 and 2 and Additional file 2, the pro-
moter CpG island of both p15INK4b and the RB1 gene are
fully unmethylated in all samples tested including HCC
and corresponding non-cancerous tissues along with the
normal liver tissues, indicating that any functional loss of
RB or p15INK4b in human HCC is not mediated by the
methylation based gene silencing mechanism that oper-
ates in several other tumor types[35]. In sharp contrast,
hypermethylation of the promoter CpG island of the
p16INK4a gene occurs overwhelmingly in HCC samples
(17/29, 58.6%) and less frequently in adjacent non-can-
cerous tissues (6/29, 20.1%) (Additional file 2, additional
file 3); while, it was unmethylated in all of the normal liv-
er tissues. Since carcinogenesis is a progressive and multi-
stage process and the so-called non-cancerous tissues clas-
sified pathologically may have already suffered some of
the genetic or/and epigenetic abnormalities which are not
unique to full-blown cancers. Any detectable abnormali-
ties exclusively in tumor tissues probably represent the ge-
netic or epigenetic lesion specific to the late-stage of
tumorgenesis. Hence, hypermethylation of the promoter
CpG island that was likely responsible for functional loss
of the p16INK4a gene in human HCC (Fig. 1 and 2 and Ad-
ditional file 2) is probably the very last definable lesion in
this disease and makes the p16INK4a gene a suitable target
for early diagnosis and genetic therapeutic remedies of
HCC in China.
The hypermethylated promoter CpG island of the RASSF1a gene co-
exists with the unmethylated promoter CpG island of the RASSF1c 
genes in the human HCC in China
RASSF1 is a recently identified tumor suppressor acting at
downstream of the Ras mediated apoptotic pathway and
capable of binding to Ras in a GTP dependent man-
ner[36]. It has two main variants, i.e., a and c, the results
of the alternative initiation of transcription along with al-
ternative splicing of the primary transcripts. RASSF1a has
a more extended 5' part and its promoter CpG island dis-
plays a tumor specific hypermethylated profile in a varietyBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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of tumors, lung cancer in particular [26,37,38]. Further-
more, lack of RASSF1a expression in nineteen established
tumor cell lines correlates with the hypermethylated state
of its promoter CpG island [38]. RASSF1c has its own pro-
moter CpG island, but is not methylated in any tumors. As
shown in Fig. 1 and Additional file 2, additional file 3, the
RASSF1a promoter-CpG island was methylated in all tu-
mor cases (29/29, 100%), but less frequently methylated
in the adjacent non-cancerous liver tissues (24/29,
82.75%). This CpG island was not methylated in any of
the four normal liver tissue samples. On the contrary, the
promoter CpG island of the C variant was unmethylated
in the entire batch of samples tested. This observation was
in accord with a previous report on human small-cell lung
cancer, where 22/29 cases (79%) had fully methylated 1A
along with unmethylated 1C variants [38]. Different
mechanisms are likely involved in the inactivation of the
RASSF1a and 1c genes, if any, in human HCC.
CASP8 is frequently methylated in both cancerous and non-cancer-
ous tissues of human HCC
CASP8, a cysteine protease is regulated in both death-re-
ceptor-dependent and independent manners during ap-
optosis. Its functional loss was previously attributed to a
DNA methylation mechanism in as many as 61% of hu-
man neuroblastoma cases [21]. As indicated in Fig. 1 and
2; Additional file 2, the promoter CpG island of the
CASP8 gene was fully methylated in all tissues from the
HCC patients tested whereas unmethylated in all four
normal liver tissues from healthy donors. This suggested
that the methylated based mechanism may contribute ex-
clusively to its inactivation in the methylated HCC cases
in China.
While CDH1 is unmethylated, CDH13 is significantly methylated in 
human HCC
The cadherins are a family of cell surface glycoproteins re-
sponsible for selective cell recognition and adhesion
[18,20,23,24]. Within this family, both CDH1 (E-cadher-
in) and CDH13 (H-cadherin) have been implicated in in-
vasion and metastasis by various solid tumors. Decreased
expression of these two genes results in cell scattering and
reduced intercellular interaction which were thought to
promote tumor progression and invasion. Recent studies
reported that methylation mediated gene silencing was a
common alternative to genetic changes for functional loss
of these two genes in human tumors [18,20,23,24]. For
instance, the methylation mediated inactivation of the
CDH13 gene occurred in 33% of breast cancers and
35.5% of tested established tumor cell lines [39]. Further-
more, there is excellent concordance between the hyper-
methylated state of the promoter CpG island and lack of
expression of the CDH 13 in both tumors and cell lines.
For the first time, the methylation state of the promoter
CpG islands of these two genes was examined in our re-
port. As shown in Fig. 1 and Additional file 2, additional
file 3, whereas the promoter CpG island of the CDH1
gene was uniformly unmethylated, tissues from 6/29
(20%) hepatoma cases and 5/29 (17.24%) matching non-
cancerous tissues revealed hypermethylated CDH13
DNA. Therefore, the methylation of the CDH13 gene rath-
er than CDH1 had some hepatoma-specific property and
may have contributed in part to the functional loss of the
CDH13 gene in human HCC.
Can methylation mediated mechanism co-operate with 
other genetic mechanisms for the tumor specific aberrant 
gene expression of the same gene?
It has been well recognized that the so-called non-cancer-
ous cells defined under microscope may have already suf-
fered some genetic lesions as have the corresponding
cancerous tissues, the outcome of earlier oncogenic
events. Both the molecular genetic diversity of tumorigen-
ic cells at various stages and the intermingled presence of
normal with tumor cells can lead to cross-contamination
of the so-called normal tissues adjacent to cancerous sam-
ples and vise versa, which are commonly used in similar
studies. Although special efforts have been made to im-
prove the quality of the samples in this study, it was not
possible to entirely eliminate cross-contamination during
our sampling process. Therefore, it is difficult to deter-
mine if the coexistence of the methylated and unmethyl-
ated target DNA segments (Fig. 1 and 2; Additional file 2)
was an inevitable consequence of cross-contamination
between tumor tissue and non-cancerous samples or a
genuine reflection of the in vivo situation.
There are several strong arguments for the latter claim.
First, over twenty genes were studied in parallel, and the
observed pattern of methylation varies dramatically with
the target segments. Second, MSP is a very sensitive meth-
od that can detect very low level contamination of DNA
that otherwise absent in patient samples. It is highly un-
likely that cross-contamination could create the observed
heterozygosity in the methylation profiles. Furthermore,
the methylation pattern of the promoter CpG island of
the p16INK4a gene varied significantly with tissues sam-
ples, even between cancerous and corresponding non-
cancerous samples from the same patient (Fig. 1 and 2;
Additional file 2). Finally, the RASSF1a gene was compa-
rably methylated to various extents between the cancerous
and non-cancerous tissues while its variant, RASSF1c, was
fully unmethylated in each case.
Therefore, coexistence of the methylated and unmethylat-
ed DNA in same patient samples, of p16INK4a, RASSF1a
and CDH1 genes, reflect the in vivo situation and have
some functional significance. HCC specific inactivation of
these three genes may indeed be attributed to both epige-
netic and genetic mechanism.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/29
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Hypermethylation of the promoter CpG island of the 
p16INK4a and RASSF1a genes is closely linked to cirrhosis in 
hepatocellular carcinoma patients in China
Methylation mediated gene silencing is a common alter-
native to the genetic lesion of genes for tumor specific ab-
errant gene expression. Inclusion of the corresponding
non-cancerous tissues in this study allowed us to address
the question as to the stage-related aspects of hypermeth-
ylation of the promoter CpG island during the process of
carcinogenesis in human HCC. In this regard, we found
that p16INK4a was heavily methylated in the tumor (17/
29, 58.6%), but much less in the matched non-cancerous
tissues (4/29, 13.3%; Additional file 2, and additional file
3). The simplest explanation is that hypermethylation of
the p16INK4a promoter CpG island is a very late event in
hepatocarcinogenesis. On the contrary, the frequency of
hypermethylation of the RASSF1a promoter in tumor (29/
29, 100%) is only slightly more than that in the corre-
sponding non-cancerous tissues (24/29, 82.75%; Addi-
tional file 2, and additional file 3). If the same logic is
applied, the methylation of the RASSF1a promoter CpG
island occurs earlier than the same event involving the
p16INK4a gene in human HCC.
For the first time, the methylation profile of the promoter
CpG islands of as many as twenty genes with proven roles
in carcinogenesis have been analyzed in human hepato-
carcinoma in China; this enabled us to determine if there
is any association in the methylation profiles among the
genes being studied as well as the gene methylation with
the clinical pathological parameters of HCC. As shown in
Additional file 2, and additional file 3, no apparent asso-
ciations were revealed in the methylation profile of each
of these four genes with the majority of the clinical-path-
ological parameters including age, geographic origin, level
of AFP in serum, size of tumors as well as whether metas-
tasis accompanied the primary lesion. On the contrary, a
close link was detected between the methylation profiles
of p16INK4a and CDH13 genes with liver cirrhosis of HCC
patients. As summarized in Tables 3 and 4, the methyla-
tion of the CDH13 gene occurs at a significantly higher
frequency in non-cirrhotic (5/13, 30.76%) than cirrhotic
patients (1/16, 6.25%) [Note, as the sample size is rela-
tively small, the association may not be statistically signif-
icant]. The opposite correlation is true for the p16INK4a
gene where methylated DNA was more frequently found
in the cirrhotic (12/16, 75%) than the non-cirrhotic group
(4/13, 33.3%). A similar conclusion was drawn with the
non-cancerous liver tissues (Table 4). Although the under-
lying mechanism for such close links among these three
parameters is not clear at the present time, such informa-
tion would certainly have substantial diagnostic value. It
is desirable to extend our study described in this report to
more patients prior to the intensive efforts in unveiling
the mystery of molecular genetic mechanisms underscor-
ing human hepatocarcinogenesis in China.
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